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OBJECTIVE. The purpose of this study was to assess which of a number of methods of
measuring attenuation on CT scans is best for prediction of hepatic fat content.
MATERIALS AND METHODS. This retrospective study was approved by our institu-
tional review board. Consecutively registered patients who underwent liver resection for met-
astatic disease formed the study group. Attenuation measurements were obtained from 12 re-
gions of interest in the liver and three in the spleen on both unenhanced and portal phase
contrast-enhanced preoperative hepatic CT images. Hepatic attenuation measurements were
analyzed both with and without normalization with the spleen. Normalization included both
differences and ratios between hepatic and splenic attenuation values. Pathologic fat content
was graded semiquantitatively as a percentage of the nonneoplastic liver parenchyma of the re-
sected specimen. Average attenuation values of the liver were compared with pathologic fat
content, as were the differences and ratios between hepatic and splenic attenuation values. Lin-
ear regression analysis was conducted on a log-log scale.
RESULTS. Data on 88 patients were analyzed. On unenhanced and contrast-enhanced CT
images, all associations between pathologic fat content and attenuation measurements were
significant (p < 0.0001). All series of R2 values for unenhanced CT scans were much higher
than those for contrast-enhanced CT scans. The R2 values of liver-only measurement were
higher than those of hepatic values normalized with splenic values on both unenhanced
(0.646–0.649 > 0.523, 0.565) and contrast-enhanced (0.516 > 0.242, 0.344) CT.
CONCLUSION. Measurement of attenuation of liver only on unenhanced CT scans is
best for prediction of pathologic fat content.
epatic steatosis, or fatty liver, is as-
sociated with obesity, alcohol con-
sumption, parenteral nutrition, and
chemotherapy [1]. It is not a rare
condition and generally causes no symptoms.
In one study [2], fatty liver was found in 24% of
histologic evaluations performed after traffic
casualties. Nonalcoholic fatty liver disease de-
fines a spectrum of changes in the liver associ-
ated with fat accumulation within the hepato-
cytes, and that spectrum encompasses both
steatosis and steatohepatitis [3]. Nonalcoholic
fatty liver disease has been suggested to be the
most common form of chronic liver disease in
adults, with an estimated prevalence of 3–29%
[4, 5]. It has been suggested that nonalcoholic
steatohepatitis be considered a progressive
form of nonalcoholic fatty liver disease that not
only significantly increases the risk of mortality
after liver resection [6] but also increases the
risk of development of cirrhosis and hepatocel-
lular carcinoma [7–9]. The degree of steatosis
that increases the morbidity rate after hepatic
resection has been reported by several authors
[1, 10, 11] to be 30%. It has also been reported
that each 1% increase in hepatic fat content, ei-
ther microvesicular or macrovesicular, de-
creases the functional mass of a donor liver 1%
[12]. In a recent study [6], steatohepatitis was
associated with a greater postoperative mortal-
ity than steatosis. The definition of steatohepa-
titis, based on nonalcoholic fatty liver disease
activity score [13], includes a cutoff of 33% for
steatosis, corresponding to two points of the
score. When the degree of hepatic steatosis be-
comes significant, the difficulty and risk asso-
ciated with major hepatic resection increase,
and function of hepatic grafts from living do-
nors is impaired [14, 15]. Thus hepatic fat con-
tent becomes an important factor to be consid-
ered before liver resection.
Histologic examination is accurate in de-
tection of hepatic fat content, but it is invasive
and time consuming, and sampling errors can
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occur. Noninvasive methods for diagnosing
fatty liver include sonography, MRI, and CT.
Among these methods, sonography is the eas-
iest, but it is only a qualitative assessment of
the fatty liver. MRI is probably the best
method for detecting a small amount of fatty
infiltration, but it is relatively expensive [16].
CT is the most widely accepted first imaging
technique for staging liver metastasis [17].
CT depicts fatty infiltration of the liver as a
decrease in attenuation [14, 18–30]. The degree
of decrease in CT attenuation has been shown
to be related to the degree of fatty infiltration of
the liver [18, 22–24]. One issue is that there are
several methods for determining the appropri-
ate CT values. These methods include measure-
ment of hepatic attenuation only [18] and nor-
malization of hepatic attenuation with splenic
attenuation, such as measurement of the differ-
ence in attenuation between liver and spleen
[19–21] and calculation of the ratio of these val-
ues [22]. To our knowledge, the methods have
not been compared. The purpose of this retro-
spective analysis was to assess which method
of measuring attenuation on CT scans is best
for prediction of hepatic fat content.
Materials and Methods
Patient Selection
We retrospectively reviewed the database of all
patients who had undergone liver resection for meta-
static disease at our institution from May 2002
through February 2004. One inclusion criterion was
that both unenhanced images and images from the
portal venous phase of contrast-enhanced CT (i.e., 60
seconds after injection of contrast material) had been
obtained before liver resection. Patients were ex-
cluded if pathologic findings had not been reviewed
for assessment of the fat content of the liver or if the
interval between preoperative CT and resection had
been greater than 6 weeks. This retrospective study
was approved by our institutional review board.
Multiphasic (triphasic or biphasic) contrast-en-
hanced and unenhanced CT scans of the liver were
evaluated for all patients included in the study.
Triphasic studies consisted of the early hepatic arte-
rial, late hepatic arterial, and portal venous phases of
contrast enhancement 20, 40, and 60 seconds after
administration of contrast medium. An IV injection
of 150 mL of nonionic iodinated contrast material
(Optiray, Mallinckrodt) was administered at a con-
centration of 320 mg I/mL and a rate of 5 mL/s. CT
was performed at 120 kVp, 240–340 mAs, 5-mm col-
limation, pitch of 1.5, and 5-mm reconstruction inter-
val. Biphasic studies consisted of late hepatic arterial
and portal venous phase images obtained approxi-
mately 40 and 60 seconds after IV injection of 150
mL of nonionic iodinated contrast material at a con-
centration of 320 mg I/mL and a rate of 3 mL/s. CT
was performed at 120 kVp, 240–340 mAs, 7.5-mm
collimation, pitch of 0.75, and 7.5-mm reconstruction
interval. Biphasic studies were generated in cases in
which patients had undergone combined chest and
abdominal CT. The images from the portal venous
phase (i.e., 60 seconds after contrast injection) were
used as contrast-enhanced images in the analyses. All
scans were obtained with 4-MDCT scanners (Light-
Speed, GE Healthcare).
Attenuation Measurements
We delineated 12 regions of interest (ROIs) within
the liver on the CT scans of each patient and obtained
the attenuation measurements for each ROI. One radi-
ologist with 11 years of experience used both unen-
hanced and contrast-enhanced CT images to delineate
the ROIs by selecting three representative levels. The
levels contained the confluence of the right hepatic
vein (Figs. 1A and 2A), the umbilical portion of the left
portal vein (Figs. 1B and 2B), and the posterior branch
of the right portal vein (Figs. 1C and 2C). At each rep-
resentative level, the liver was apportioned into four
sectors (right posterior, right anterior, left medial, and
left lateral). These sectors were defined with a modifi-
cation of the Couinaud [31] segmentation system. The
right posterior sector included segments VI and VII,
the right anterior sector included segments V and VIII,
the left medial sector included segment IV, and the left
lateral sector included segments II and III. One ROI
randomly drawn inside each sector, avoiding the large
vessels and any focal lesions, was considered represen-
tative of the sector. Each ROI measured 1.0 ± 0.1 cm2.
We also drew one ROI inside the spleen in each repre-
sentative slice (Fig. 2).
Pathologic Fat Content
Pathologic fat content was measured in represen-
tative H and E slides from the resected liver speci-
men. In each case, one pathologist with 5 years of ex-
perience who had expertise in gastrointestinal and
hepatic pathology graded the degree of steatosis us-
ing slides of tissue specimens from nonneoplastic
liver parenchyma at least 2 cm away from the meta-
static tumor. The degree of steatosis was graded
semiquantitatively as the percentage of liver paren-
chyma involved by fatty infiltration, estimated to the
nearest 5%. When the degree of involvement was
less than 5%, it was estimated to the nearest 1%.
Statistical Analysis
For each patient, average attenuation in the ROIs
in whole sectors of the liver and that in the resected
sectors of the liver was calculated on both unen-
hanced and contrast-enhanced CT scans. A sector
was considered resected only if it actually con-
tained a resected segment. For example, in the case
of a patient who had undergone right extended
hepatectomy, the right posterior, right anterior, and
left medial sectors were defined as resected sectors.
The average attenuation of the ROIs in the spleen
also was calculated.
We first transformed the value for pathologic fat
content to –log[–log (pathologic fat content)]. This is
a common transformation for proportions to meet
the normality assumptions of the least-squares linear
regression model. Because pathologic fat content
values less than 1 were undefined in this transforma-
tion, such values were imputed with Markov chain
Monte Carlo methods (20,000 replicates). Linear re-
gression equations for prediction of the transformed
pathologic fat content were estimated from whole-
liver attenuation, attenuation of whole liver minus
spleen, ratio of whole-liver attenuation to splenic at-
tenuation, attenuation of the resected portion of the
liver, attenuation of the resected portion of the liver
minus the spleen, and ratio of resected liver attenua-
tion to splenic attenuation. Coefficient of determina-
tion (R2), mean square error of the regression line
(S2), and p values were calculated. In comparisons of
regression models, larger R2 values and smaller S2
values imply superior predictive ability.
Back-transformed estimates of the predicted
pathologic fat content with 90% CIs have a sensible
lower bound of zero. Regressions incorporating
Markov chain Monte Carlo methods were con-
ducted with R Project software (R Foundation for
Statistical Computing) (free software available at:
www.r-project.org). Graphs of observed and pre-
dicted models with 90% CIs were constructed with
S-Plus software (Insightful).
Results
During the study period, 157 patients under-
went liver resection for metastatic disease at our
institution. Fifty-eight of the patients were ex-
cluded from analysis because they did not un-
dergo both unenhanced and contrast-enhanced
CT. Eight patients were excluded because
pathologic findings were not available, and
three were excluded because the interval be-
tween preoperative CT and resection was
greater than 6 weeks. Thus data on 88 patients
formed the basis of this retrospective study.
Forty-two of the 88 patients were women. The
median age at resection was 58 years (range,
18–81 years), and the mean interval between
preoperative CT and resection was 16.4 days
(range, 1–36 days). The mean number of he-
patic metastatic lesions was 2.6 (range, 1–12 le-
sions). Multiphasic (59 triphasic, 29 biphasic)
contrast-enhanced and unenhanced CT scans of
the liver were available for all 88 patients.
Table 1 shows the data (mean ± SD) for all
attenuation calculations for both unenhanced
and contrast-enhanced CT scans. Table 2
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shows the mean (± SD) data for attenuation
calculations for unenhanced CT scans catego-
rized by pathologic fat content. Overall, the
mean pathologic fat content was 12.9% ±
16.9% (range, 0–70%). This value includes
data on the 19 (22%) of the patients in whom
no fat was detected in the liver. All regression
estimates of the slopes predicting pathologic
fat content from attenuation calculations for
both unenhanced and contrast-enhanced CT
scans were statistically significant at p <
0.0001 (Table 3). All series of R2 values for the
unenhanced CT scans were much higher than
those for the contrast-enhanced images
(Table 3). The difference in R2 values between
whole-liver attenuation and resected-liver at-
tenuation was very small for both unenhanced
(0.649 and 0.646) and contrast-enhanced CT
images (0.516 and 0.516). The R2 values for
whole-liver attenuation and resected-liver at-
tenuation without comparison with splenic at-
tenuation were higher than the values in which
splenic measurements were considered (i.e.,
whole liver minus spleen, resected liver minus
spleen, ratio of whole-liver to splenic attenua-
tion, and ratio of resected-liver to splenic atten-
uation) on both unenhanced (0.646–0.649 >
0.523–0.565) and contrast-enhanced (0.516 >
0.242–0.344) images (Table 3).
The regression line of pathologic fat content
versus unenhanced resected-liver attenuation
was pathologic fat content = exp[–exp(–1.915 +
0.051 × resected-liver attenuation)] and is plot-
ted in Figure 3A along with observed patho-
logic fat content values. On the basis of this re-
gression equation, if the liver attenuation on
unenhanced CT scans is 40 H, the predicted he-
patic fat content is approximately 30%. Simi-
larly, if the unenhanced CT attenuation is 30 H,
the predicted hepatic fat content is approxi-
mately 50%. The regression line of pathologic
fat content versus contrast-enhanced resected-
liver attenuation was pathologic fat content =
exp[–exp(–1.781 + 0.024 × resected-liver at-
tenuation)] and is plotted in Figure 3B along
with the observed pathologic fat content values.
Discussion
We found that the best method of predicting
pathologic fat content in the liver is simple mea-
surement of liver attenuation on unenhanced CT
scans. Previous reports have shown unenhanced
CT images to be good for prediction of the de-
gree of fatty infiltration of the liver [18, 22–24].
Ducommun et al. [18] and Kawata et al. [23]
found that attenuation of the liver on CT scans
accurately reflected pathologic fat content in
rabbits. Ricci et al. [22] reported that fat content
in the liver, represented by a fat-containing tube
model, had a linear correlation with CT attenu-
ation. Wang et al. [24] suggested that dual-en-
ergy CT was useful for making a quantitative di-
agnosis of fatty liver in a rabbit model.
A B
C
Fig. 1—Regions of interest for measurement of attenuation. Sectors and borders are 
defined with modification of Couinaud segmentation system. Dashed lines indicate 
borders between sectors. RHV = right hepatic vein, MHV = middle hepatic vein, 
IVC = inferior vena cava.
A, Schematic shows level of confluence of right hepatic vein. LHV = left hepatic vein.
B, Schematic shows level of umbilical portion (UP) of left portal vein.
C, Schematic shows level of posterior branch of right portal vein (PPV). APV = 
anterior branch of right portal vein.
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In our study, all series of R2 values for the
unenhanced CT images were much higher
than those for the contrast-enhanced images,
indicating that contrast-enhanced CT was not
the most suitable method for prediction of he-
patic fat content. This finding was similar to
those previously reported [20, 21]. On con-
trast-enhanced CT, attenuation is greatly af-
fected by the concentration of the contrast
A B
C
Fig. 2—64-year-old woman with liver metastasis. Dashed lines indicate borders 
between sectors. IVC = inferior vena cava.
A, CT scan corresponding to 1A shows regions of interest at level of confluence of 
right hepatic vein.
B, CT scan corresponding to 1B shows regions of interest at level of umbilical portion 
of left portal vein.
C, CT scan corresponding to 1C shows regions of interest at level of posterior branch 
of right portal vein.
TABLE 1: Attenuation Values
CT Type Whole Liver
Resected Portion 
of Liver Spleen
Whole Liver 
Minus Spleen
Resected Portion 
of Liver 
Minus Spleen
Ratio Between 
Whole Liver 
and Spleen
Ratio Between 
Resected Liver 
and Spleen
Unenhanced
Average attenuation (H) 56.5 56.4 53.0 3.6 3.4 1.07 1.07
SD 11.7 11.7 4.5 11.3 11.3 0.23 0.23
Contrast-enhanced
Average attenuation (H) 116.0 116.5 132.7 –16.7 –16.2 0.88 0.88
SD 24.0 24.4 22.0 20.6 21.1 0.15 0.15
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medium, which is greatly affected by volume,
rate of administration, and circulation of con-
trast material and the timing of measurements
[20]. We used two different injection rate pro-
tocols, which likely contributed to the vari-
ability. The SD of attenuation in contrast-en-
hanced series was larger than in unenhanced
series. Thus any difference in attenuation due
to fat content was masked by the effect of the
contrast medium, which resulted in a decrease
in prediction power.
The spleen provides a suitable organ to
which the liver might potentially be normal-
ized. Overall splenic attenuation is not affected
by most diffuse pathologic processes, and the
spleen is usually located on the same axial CT
slice as the liver, making it easy to measure the
attenuation [20]. In our study, we measured at-
tenuation not only of the liver but also of the
spleen and analyzed both the differences and
the ratios between the hepatic and splenic atten-
uation values.
In comparisons of attenuation measurements
of liver only and of liver normalized with
spleen, the R2 values of liver only were higher
than those of liver normalized with spleen. The
difference was not small, indicating that atten-
uation measurement in the spleen did not con-
tribute to the prediction of hepatic fat content.
We were somewhat surprised by this result be-
cause we were anticipating a normalizing effect
with the inclusion of splenic measurement.
The R2 value of resected-liver attenuation
was a bit smaller than that of whole-liver atten-
uation, although this difference was inconse-
quential. We expected that the attenuation of
the resected portions of the liver would be
TABLE 2: Attenuation Categorized by 
Pathologic Fat Content on 
Unenhanced CT
Pathologic Fat
Content (%) No.
Attenuation (H)a
Whole Liver
Resected 
Portion of 
Liver
0 19 64.4 ± 3.1 63.9 ± 3.7
1–25 54 59.1 ± 7.3 59.1 ± 7.1
26–50 11 41.9 ± 6.7 40.8 ± 7.2
> 50 4 25.0 ± 15.5 26.2 ± 14.9
aValues are mean ± SD.
TABLE 3: Results of Linear Regression Analysis
Value Whole Liver
Resected Portion 
of Liver
Whole Liver 
Minus Spleen
Resected Portion of 
Liver Minus Spleen
Ratio Between 
Whole Liver 
and Spleen
Ratio Between 
Resected Portion of 
Liver and Spleen
Unenhanced CT
R2 0.649 0.646 0.565 0.555 0.535 0.523
S2 0.198 0.200 0.252 0.259 0.270 0.279
Contrast-enhanced CT
R2 0.516 0.516 0.251 0.242 0.344 0.331
S2 0.325 0.329 0.483 0.487 0.411 0.420
Note—All series of comparisons between pathologic fat content and attenuation calculations are p < 0.0001. R2 = coefficient of determination, S2 = mean square error of 
regression line.
A B
Fig. 3—Fat content versus attenuation.
A, Graph shows results for unenhanced CT images. Solid line indicates predictive equation for pathologic fat content given attenuation of resected portion of liver. Pathologic 
fat content = exp[–exp(–1.915 + 0.051 × resected-liver attenuation)]. Dashed lines indicate upper and lower 90% bounds of pathologic fat content.
B, Graph shows results for contrast-enhanced CT images. Solid line indicates predictive equation for pathologic fat content given attenuation of resected portion of liver. 
Pathologic fat content = exp[–exp(–1.781 + 0.024 × resected-liver attenuation)]. Dashed lines indicate upper and lower 90% bounds of pathologic fat content.
Mean Attenuation Value (H) in Resected Liver
Fa
t P
er
ce
n
ta
ge
0 20 40 60 80 100
0
20
40
60
80
Mean Attenuation Value (H) in Resected Liver
Fa
t P
er
ce
n
ta
ge
0 50 100 150 200
0
20
40
60
80
D
ow
nl
oa
de
d 
fro
m
 w
w
w
.a
jro
nli
ne
.or
g b
y 1
85
.3.
20
.29
 on
 11
/15
/15
 fr
om
 IP
 ad
dre
ss 
18
5.3
.20
.29
. C
op
yri
gh
t A
RR
S. 
Fo
r p
ers
on
al 
use
 on
ly;
 al
l ri
gh
ts 
res
erv
ed
 
Kodama et al.
1312 AJR:188, May 2007
more useful than that of whole liver for predic-
tion of fat content, which was obtained from
the resected portions of liver. The difference
was very small, however, leading us to con-
clude that there is no difference in predictive
capacity between the attenuation of whole liver
and that of resected liver segments.
We recognize that this study had limitations.
First, the exact sites from which the pathologic
sections were obtained for evaluation of patho-
logic fat content were not precisely defined.
Thus we did not undertake location-to-location
correlation between the pathologic specimens
and the attenuation measurements. Second, liver
attenuation is affected not only by fat infiltration
but also by other metabolic conditions, such as
iron deposition [32] and hepatic edema, as in
hepatitis. When fatty infiltration and iron deposi-
tion coexist, a change in attenuation of the liver
can be masked [15]. Third, focal fatty infiltration
sometimes occurs, and in those cases, attenua-
tion of the liver is heterogeneous rather than ho-
mogeneous [25, 26]. Because it is difficult to de-
fine the degree of heterogenicity, we included all
cases, even those with heterogenicity. We mea-
sured a large number of ROIs and used the aver-
age value for analysis. We believe that this
method minimizes the effect of heterogenicity.
Comparison of hepatic attenuation with
splenic attenuation is a more complex method
than measuring liver attenuation alone. The
liver–spleen method requires more time and ef-
fort. Because our results showed that splenic
measurements did not contribute to accurate
prediction of fat content, we consider compari-
son methods unnecessary. Simple liver attenua-
tion measurement not only saves time and effort
but also gives an intelligible and useful result.
It has been suggested [1, 10, 11] that a he-
patic fat content greater than 30% increases
the risk of morbidity after hepatic resection.
For this reason, it also has been suggested
[15] that persons with a hepatic fat content
greater than 30% should not be liver donors.
Results with our regression model indicate
that a practical cutoff value for predicting
30% liver fat content may be an attenuation of
40 H on unenhanced CT scans. We conclude
that radiologists and clinicians can use liver-
only attenuation to easily define the degree of
fatty infiltration of the liver.
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